ArticleInternal medicine (Tokyo, Japan)2026
Exosomal hsa-miR-3649 and hsa-miR-202-3p in Gastric Juice as Potential Biomarkers for Functional Dyspepsia with a Previous Helicobacter pylori Infection.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Specific microRNAs (miRNAs) in patients with functional dyspepsia (FD) and previous Helicobacter pylori (HP) infections have not been elucidated. This study aimed to investigate exosomal miRNAs as potential biomarkers of FD in patients with a previous HP infection using a liquid biopsy. Methods Six patients with FD and six age- and sex-matched healthy controls (HCs) with a previous HP infection were enrolled in the discovery cohort. Gastric juice and isolated exosomal miRNAs were collected. Subsequently, the expression of 2,565 miRNAs was evaluated by a microarray analysis, and FD-specific miRNAs were detected. Eight patients with FD and eight HCs were enrolled in the validation cohort. miRNA expression was validated by quantitative reverse transcription-polymerase chain reaction. Results A microarray analysis identified five significantly downregulated miRNAs (hsa-miR-4738-3p, hsa-miR-5697, hsa-miR-8068, hsa-miR-3148, and hsa-miR-4521) and four significantly upregulated miRNAs (hsa-miR-3649, hsa-miR-451b, hsa-miR-202-3p, and hsa-miR-502-3p) in FD patients compared with HCs. In a validation study, three miRNAs were significantly upregulated in patients with FD (hsa-miR-3649, hsa-miR-202-3p, and hsa-miR-3148). The level of hsa-miR-3178 was inversely correlated with that observed in the discovery study. Furthermore, hsa-miR-3649 and hsa-miR-202-3p were significantly upregulated in patients with FD compared to HC (64.893±60.847-fold, p=0.0104; 14.906±15.022-fold, p=0.0379, respectively), and their expression was positively associated with the frequency of early satiation (p=0.0438, r=0.509; p=0.0256, r=0.555, respectively). Conclusion Exosomal hsa-miR-3649 and hsa-miR-202-3p may therefore be candidate biomarkers for FD in patients with previous HP infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.